medRxiv : the preprint server for health sciences · 2025
DNA methylation-wide association study of prevalent and incident dementia in the US Health and Retirement Study.
СтатьяПрепринтНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dou John, Cockell Scarlet, Wang Herong, Hemenway Nathan, Ryan Lindsay, Zawistowski Matt, Ware Erin B, Bakulski Kelly M
Аннотация
BACKGROUND: Peripheral blood DNA methylation may have utility as an early dementia risk biomarker.
METHODS: We analyzed DNA methylation (blood collected 2016) and cognitive impairment in the Health and Retirement Study, a longitudinal study representative of US adults over age 50 (3,921 individuals and 585,356 CpG sites). We analyzed methylation associations with cognitive status both cross-sectionally and prospectively among participants with normal cognition at baseline with four years follow-up.
RESULTS: Cross-sectionally, 5,322 CpGs were associated (p-value<0.01) with cognitive impairment non-dementia, and 14,366 (166 genome-wide FDR<0.05) with dementia. Prospectively, 4,898 CpGs were associated with any-impairment. Enriched biologic pathways include ion transport, ligand-gated channel, and neuron differentiation. Nine CpGs overlapped all analyses including cg02583484 (HNRNPA1), cg15266133 (LOC102724084), cg24287460 (CCDC48), cg17124509 (C17orf57), and cg02553054 (SMARCD1).
DISCUSSION: CpGs identified were enriched in pathways related to Alzheimer's disease pathology and provide promising grounds for non-invasive blood biomarkers. Future studies for replication and with longer follow-up are needed.
METHODS: We analyzed DNA methylation (blood collected 2016) and cognitive impairment in the Health and Retirement Study, a longitudinal study representative of US adults over age 50 (3,921 individuals and 585,356 CpG sites). We analyzed methylation associations with cognitive status both cross-sectionally and prospectively among participants with normal cognition at baseline with four years follow-up.
RESULTS: Cross-sectionally, 5,322 CpGs were associated (p-value<0.01) with cognitive impairment non-dementia, and 14,366 (166 genome-wide FDR<0.05) with dementia. Prospectively, 4,898 CpGs were associated with any-impairment. Enriched biologic pathways include ion transport, ligand-gated channel, and neuron differentiation. Nine CpGs overlapped all analyses including cg02583484 (HNRNPA1), cg15266133 (LOC102724084), cg24287460 (CCDC48), cg17124509 (C17orf57), and cg02553054 (SMARCD1).
DISCUSSION: CpGs identified were enriched in pathways related to Alzheimer's disease pathology and provide promising grounds for non-invasive blood biomarkers. Future studies for replication and with longer follow-up are needed.